Search form

Search form

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.

Related Summaries

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.

FDA officials seem to be taking a more cautious approach to drug evaluation after the agency restricted access to GlaxoSmithKline's diabetes pill Avandia because of heart risk, said industry executives and experts during the Reuters Health Summit. "There's no doubt in my mind that the FDA has become significantly more stringent in evaluating all drugs, especially diabetes drugs," Novo Nordisk CEO Lars Sorensen said.